Published • loading... • Updated
AbbVie's Migraine Franchise Scored a Big Win. Is This Dividend King a No-Brainer Buy Right Now?
Summary by The Motley Fool
1 Articles
1 Articles
AbbVie's Migraine Franchise Scored a Big Win. Is This Dividend King a No-Brainer Buy Right Now?
Key PointsAbbVie's Qulipta could be racing toward another label expansion, given a recent clinical trial win.This new indication could make a meaningful impact on Qulipta's sales.However, AbbVie's most important growth opportunities lie elsewhere. 10 stocks we like better than AbbVie › AbbVie (NYSE: ABBV), a pharmaceutical giant, is best known for its work in immunology. Over the decade between 2013 (when it became a stand-alone publicly traded …
·Alexandria, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left1Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium
